Charles River Laboratories
$ 187.51
-0.29%
12 Jun - close price
- Market Cap 9,031,931,000 USD
- Current Price $ 187.51
- High / Low $ 190.79 / 185.16
- Stock P/E N/A
- Book Value 61.05
- EPS -3.71
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE -0.06 %
- 52 Week High 228.88
- 52 Week Low 143.06
About
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Analyst Target Price
$212.27
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-18 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-19 | 2024-11-06 | 2024-08-07 | 2024-05-09 | 2024-02-14 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.3 | 2.39 | 2.43 | 3.12 | 2.34 | 2.66 | 2.59 | 2.8 | 2.27 | 2.46 | 2.72 | 2.69 |
| Estimated EPS | 0.91 | 2.35 | 2.34 | 2.55 | 2.07 | 2.53 | 2.42 | 2.39 | 2.06 | 2.4 | 2.37 | 2.64 |
| Surprise | -1.21 | 0.04 | 0.09 | 0.57 | 0.27 | 0.13 | 0.17 | 0.41 | 0.21 | 0.06 | 0.35 | 0.05 |
| Surprise Percentage | -132.967% | 1.7021% | 3.8462% | 22.3529% | 13.0435% | 5.1383% | 7.0248% | 17.1548% | 10.1942% | 2.5% | 14.7679% | 1.8939% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 2.72 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRL
2026-06-14 19:05:00
Charles River Laboratories stock is drawing attention from US investors due to a recent reset in valuation multiples and its solid, though normalized, revenue and earnings growth. The company, a specialist in early-stage drug discovery and non-clinical development, continues to expand in high-value services like biologics and cell/gene therapy support, despite facing inflationary pressures and transitioning away from hyper-growth expectations. Its diversified client base and strategic investments in capacity position it as a steady compounder in the contract research space, with analysts noting a more balanced risk-reward profile after prior market highs.
2026-06-13 08:10:14
Jong Ik Kwon, a long-term shareholder and veterinary clinician, proposes a strategic repositioning of Inotiv from a traditional laboratory animal supplier to an "Inotiv NAMs Test Center." This involves converting existing underutilized facilities into advanced laboratories for New Approach Methodologies (NAMs), such as organoids and advanced analytics, to offer high-value decision-support services. The aim is to improve margins, enhance ESG positioning, and align Inotiv with evolving industry trends in preclinical research.
2026-06-12 11:26:00
Charles River Labs (CRL) saw its stock pull back due to fears of AI disruption in the drug development sector, despite its shares gaining significantly over the past year. Madison Small Cap Fund, a holder of CRL, believes these disruption fears are "overexaggerated," arguing that AI will increase demand for clinical research services and enhance efficiency for larger contract research organizations like Charles River Labs. The fund maintains enthusiasm for its investment and has selectively added to its positions in CRL.
2026-06-12 11:24:00
The Madison Small Cap Fund increased its stake in Medpace Holdings (MEDP) despite the stock pulling back due to AI disruption fears. The fund believes these fears are overblown, arguing that AI will enhance drug development efficiency and increase demand for clinical research services, benefiting larger CROs like Medpace. While Medpace is not among their top AI stock picks, the fund maintains enthusiasm for its investment and selectively added to its position.
2026-06-11 10:47:25
Danaher (DHR) has seen its stock price recover recently, gaining 3.1% in the past week and 10.3% over the last month, despite being down year-to-date and over the last year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 18.0% at $183.63 per share, while its P/E ratio of 35.37x indicates it is overvalued compared to Simply Wall St's proprietary "Fair Ratio" of 29.29x, prompting a mixed valuation outlook dependent on the chosen analysis method.
2026-06-10 17:17:00
Charles River Laboratories International Inc. (CRL) stock fell by 1.88% on Wednesday, closing at $186.29. This underperformance occurred during a broader market decline, with the S&P 500 Index and Dow Jones Industrial Average also experiencing drops. The stock's decline ended a two-day winning streak.
